Jiangsu Nhwa Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangsu Nhwa Pharmaceutical Co Ltd (002262.CS)

Q3 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

September 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Latest17 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.